122 related articles for article (PubMed ID: 6864917)
21. Genetic polymorphisms of N-acetyltransferase 1 and 2 and risk of cigarette smoking-related bladder cancer.
Hsieh FI; Pu YS; Chern HD; Hsu LI; Chiou HY; Chen CJ
Br J Cancer; 1999 Oct; 81(3):537-41. PubMed ID: 10507782
[TBL] [Abstract][Full Text] [Related]
22. Urinary bladder cancer in a girl with a slow-acetylator genotype and treated with sulphasalazine.
Filiadis IF; Georgiou IA; Giannakopoulos X
Br J Urol; 1998 Feb; 81(2):342-3. PubMed ID: 9488096
[No Abstract] [Full Text] [Related]
23. NAT2 gene polymorphism in bladder cancer: a study from North India.
Mittal RD; Srivastava DS; Mandhani A
Int Braz J Urol; 2004; 30(4):279-85; discussion 285-8. PubMed ID: 15679955
[TBL] [Abstract][Full Text] [Related]
24. Role of N-acetyltransferase phenotypes in bladder carcinogenesis: a pharmacogenetic epidemiological approach to bladder cancer.
Cartwright RA; Glashan RW; Rogers HJ; Ahmad RA; Barham-Hall D; Higgins E; Kahn MA
Lancet; 1982 Oct; 2(8303):842-5. PubMed ID: 6126711
[TBL] [Abstract][Full Text] [Related]
25. Association Between N-acetyltransferase 2 Polymorphism and Bladder Cancer Risk: Results From Studies of the Past Decade and a Meta-Analysis.
Wu H; Wang X; Zhang L; Mo N; Lv Z
Clin Genitourin Cancer; 2016 Apr; 14(2):122-9. PubMed ID: 26585839
[TBL] [Abstract][Full Text] [Related]
26. Commentary: Reflections on G. M. Lower and colleagues' 1979 study associating slow acetylator phenotype with urinary bladder cancer: meta-analysis, historical refinements of the hypothesis, and lessons learned.
Rothman N; Garcia-Closas M; Hein DW
Int J Epidemiol; 2007 Feb; 36(1):23-8. PubMed ID: 17510073
[No Abstract] [Full Text] [Related]
27. Higher DNA adduct levels in urinary bladder and prostate of slow acetylator inbred rats administered 3,2'-dimethyl-4-aminobiphenyl.
Jiang W; Feng Y; Hein DW
Toxicol Appl Pharmacol; 1999 May; 156(3):187-94. PubMed ID: 10222311
[TBL] [Abstract][Full Text] [Related]
28. Genetically determined variability in acetylation and oxidation. Therapeutic implications.
Clark DW
Drugs; 1985 Apr; 29(4):342-75. PubMed ID: 2859977
[TBL] [Abstract][Full Text] [Related]
29. [Relationship between genetic polymorphism of NAT2 and susceptibility to urinary bladder cancer].
Hao GY; Zhang WD; Chen YH; Zhang DX; Zhang YH
Zhonghua Zhong Liu Za Zhi; 2004 May; 26(5):283-6. PubMed ID: 15312364
[TBL] [Abstract][Full Text] [Related]
30. Molecular pathways in bladder cancer: part 1.
Bryan RT; Hussain SA; James ND; Jankowski JA; Wallace DM
BJU Int; 2005 Mar; 95(4):485-90. PubMed ID: 15705065
[No Abstract] [Full Text] [Related]
31. Genetically determined N-acetylation and oxidation capacities in Japanese patients with non-occupational urinary bladder cancer.
Horai Y; Fujita K; Ishizaki T
Eur J Clin Pharmacol; 1989; 37(6):581-7. PubMed ID: 2612554
[TBL] [Abstract][Full Text] [Related]
32. Refinement of the prediction of N-acetyltransferase 2 (NAT2) phenotypes with respect to enzyme activity and urinary bladder cancer risk.
Selinski S; Blaszkewicz M; Ickstadt K; Hengstler JG; Golka K
Arch Toxicol; 2013 Dec; 87(12):2129-39. PubMed ID: 24221535
[TBL] [Abstract][Full Text] [Related]
33. N-acetylation phenotype in bladder cancer.
Woodhouse KW; Adams PC; Clothier A; Mucklow JC; Rawlins MD
Hum Toxicol; 1982 Oct; 1(4):443-5. PubMed ID: 7173929
[TBL] [Abstract][Full Text] [Related]
34. Polymorphic N-acetylation of sulfamethazine and benzidine by human liver: implication for cancer risk?
Peters JH; Gordon GR; Lin E; Green CE; Tyson CA
Anticancer Res; 1990; 10(1):225-9. PubMed ID: 2334132
[TBL] [Abstract][Full Text] [Related]
35. N-acetylation phenotype and genotype and risk of bladder cancer in benzidine-exposed workers.
Hayes RB; Bi W; Rothman N; Broly F; Caporaso N; Feng P; You X; Yin S; Woosley RL; Meyer UA
Carcinogenesis; 1993 Apr; 14(4):675-8. PubMed ID: 8472331
[TBL] [Abstract][Full Text] [Related]
36. [Acetylation phenotype in patients with cancer of the bladder. Preliminary report].
Skretowicz J; Polakowski P; Jeromin L; Zasada M; Szymańska J; Krajewska B
Med Pr; 1988; 39(4):241-5. PubMed ID: 3237058
[TBL] [Abstract][Full Text] [Related]
37. Epidemiological models of carcinogenesis: the example of bladder cancer.
Vineis P
Cancer Epidemiol Biomarkers Prev; 1992; 1(2):149-53. PubMed ID: 1306098
[TBL] [Abstract][Full Text] [Related]
38. N-acetyltransferase 2 phenotype but not NAT1*10 genotype affects aminobiphenyl-hemoglobin adduct levels.
Probst-Hensch NM; Bell DA; Watson MA; Skipper PL; Tannenbaum SR; Chan KK; Ross RK; Yu MC
Cancer Epidemiol Biomarkers Prev; 2000 Jun; 9(6):619-23. PubMed ID: 10868698
[TBL] [Abstract][Full Text] [Related]
39. Acetylation.
Weber WW
Birth Defects Orig Artic Ser; 1990; 26(1):43-65. PubMed ID: 2224079
[TBL] [Abstract][Full Text] [Related]
40. Genetic aberrations of the K-ras proto-oncogene in bladder cancer in Kashmiri population.
Nanda MS; Sameer AS; Syeed N; Shah ZA; Murtaza I; Siddiqi MA; Ali A
Urol J; 2010; 7(3):168-73. PubMed ID: 20845292
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
